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$1239: outpatient care). Though the overall predictive
power of the model was low (R2  0.10), the most sig-
nificant predictors of increased total cost were: CGIm-
pression (P  .001), SOFAS (P  .014), ethnicity (P 
.001), and onset age (P  .080). CONCLUSIONS: Inpa-
tient care represents the largest component (42%) of the
total cost of care for patients in this study. Costs are
higher for Caucasian patients, patients with later onset of
disease, and patients with more severe disease measured
by CGImpressions and SOFAS. Whether the use of more
effective medications will decrease hospitalization and to-
tal costs remains to be determined.
PMH15
ECONOMIC EVALUATION OF REBOXETINE FOR 
TREATING MAJOR DEPRESSION
Sheriff SK1, Levaux HP1, Villa KF1, Schonfeld WH1, Rowland 
C2, Williamson TE2
1The Lewin Group, San Francisco, CA, USA; 2Pharmacia 
Corporation, Peapack, NJ, USA
Complete economic evaluations of new antidepressants
should consider the impact of depression on productivity
costs associated with impaired work performance and
other disability as well as on direct medical costs. OB-
JECTIVES: This study compares costs and effectiveness
of reboxetine and fluoxetine for treating major depres-
sion, focusing on the productivity improvements associ-
ated with each treatment. METHODS: A semi-Markov
model was constructed describing the course of depres-
sion and its treatment. The model combines efficacy data
from two head-to-head clinical trials of reboxetine and
fluoxetine with resource use estimates from expert opin-
ion elicited by questionnaire. Unit costs for resources
were obtained from the medical literature. The number
of disability days associated with each health state in the
model was estimated from population surveys and clini-
cal trial information. The model generated cost-effective-
ness measures for the total population as well as the sub-
set of severe patients (defined as patients with baseline
Clinical Global Impression severity scores of “markedly
ill”, “severely ill”, or “among the most extremely ill”) found
in the clinical trials. RESULTS: Model results showed no
significant differences in effectiveness between the two
treatment groups. For the total population, annual direct
medical and productivity costs totaled $6679 for rebox-
etine and $6958 for fluoxetine. Among severe patients,
total costs were $6946 for reboxetine and $7491 for flu-
oxetine. Productivity costs accounted for approximately
50% of the total cost of depression in both treatment
groups and patient populations. Sensitivity analyses con-
firmed the model’s robustness. CONCLUSIONS: The model
shows reboxetine to be cost saving compared to fluoxet-
ine for the treatment of major depression. The majority
of savings results from improvements in patient produc-
tivity, with the greatest potential for savings found in the
severe patient population. 
PMH16
RELAPSE IN SCHIZOPHRENIA: COSTS AND 
QUALITY OF LIFE
Brugha T1, Almond S2, Francois C3, Toumi M3
1Section of Social & Epidemiological Psychiatry, University of 
Leicester Department of Psychiatry, Leicester, UK; 2Personal 
Social Services Research Unit, London School of Economics & 
Political Science, London, UK; 3Lundbeck S.A., Paris, France
OBJECTIVE: To compare the costs and quality of life of
77 patients who relapse with a control group of 68 non-
relapse patients, in schizophrenia. METHODS: Patients
were selected from current (active) psychiatric caseloads
drawn from urban, suburban and rural Leicester and Leices-
tershire. Relapse cases were identified by the re-emer-
gence and aggravation of symptoms, and by psychiatric
in-patient re-admissions, current or within the last 6 months.
Data collection included: social and demographic pro-
files, DSM IV classification, PANSS, CGI, GAF, Quality
of Life (Lehman), EuroQol, and health care utilization.
Standard parametric/non-parametric tests are used to test
for differences in outcomes and costs for relapse and
non-relapsing patients. Hypothesis-driven analyses focus
on the correlates of quality of life, links between symp-
toms and functioning, socio-economic consequences of
schizophrenia, and cost consequences of positive symp-
toms and functioning deficits. Standard multivariate analysis
will identify key determinants of costs, and Generalized
Linear Models will be used to predict relapse status. Pro-
visional results confirm higher costs and lower quality of
life for patients who relapse. CONCLUSIONS: Schizo-
phrenia is a long-term, debilitating and costly illness. Po-
tentially high costs are incurred by health care providers,
social services and other care agencies, and by families
and sufferers themselves. One of the most costly aspects
of schizophrenia is associated with illness relapse, which
has been estimated, for example, to cost $2 billion in re-
admission costs in the US. There is currently no equiva-
lent estimate for the UK. The findings from this study
will be of interest to policy-makers who face difficult eco-
nomic choices concerning new but more expensive drug
treatments for patients with schizophrenia. The challenge
for new antipyschotic treatments is to improve efficacy
and compliance and thereby reduce relapse rates. In turn
this would be expected to bring about reductions in the
total national costs of schizophrenia, whilst also improv-
ing the welfare of patients.
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OBJECTIVE: To assess utilization patterns, frequency of
side effects, and the cost of side effects associated with
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SSRI treatment. METHODS: Electronic medical records
and medication profiles from HMO patients were retro-
spectively reviewed. Inclusion criteria were patients over
18 years old with a new prescription for an SSRI who
were continuously enrolled in the HMO plan for at least
one year (6 months before and 6 months after their index
date). The perspective was that of the HMO. RESULTS:
Of the 464 patients who met the inclusion criteria, 130
patients (28%) had 144 medication changes made after
initial therapy, including 43 additions of medication, 43
switches to another antidepressant, 41 discontinuations
of therapy due to side effects, and 17 dose changes due to
side effects. A total of 160 patients (34%) had at least
one side effect of the SSRI noted in their medical record.
Costs to treat side effects were estimated for changes/
additions of medication that appeared in the medication
profiles (38 patients). The cost of added medications that
were noted in the medical record but did not appear in
the medication profile (e.g. non-prescription items such
as Immodium) were not included in the estimate due to
the perspective of the study. Other costs associated with
side effects included physician visits (43 patients), lab
tests for dosage adjustments (4 patients), and emergency
room visits (3 patients). Sensitivity analyses indicated that
the direct medical costs associated with the treatment of
side effects ranged from approximately $4600 US to $6000
US for the 464 patients ($10 US-$13 US per patient) for
the six-month period of analysis. CONCLUSION: Al-
though one-third of patients noted at least one side effect
of SSRI treatment, the direct medical costs associated
with the side effects were relatively small. Future studies
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OBJECTIVE: Pamidronate prevents skeletal-related events
in breast cancer patients with skeletal metastasis, but it
costs $175 per month and published cost-utility analyses
have yielded conflicting results. The purpose of our study
was to rigorously evaluate the cost-utility of pamidr-
onate. METHODS: We considered two hypothetical co-
horts of woman with metastatic breast cancer receiving
or not pamidronate (90 mg every 28 days). We developed
a 24-month-long Markov chain including 5 health states
related to skeletal metastases (chronic bone pain, acute
fracture, vertebral or non-vertebral, post-fracture, verte-
bral or non-vertebral) and death. Probabilities of clinical
outcomes were obtained from two randomized clinical
trials addressing chemotherapy-treated (CTPs) and hor-
mone-treated (HTPs) patients. Cost estimates were de-
rived from local hospital charges and market cost of
drugs. Quality of life estimates were obtained with a
structured time trade-off interview of 20 health care
workers. Cost-effectiveness was calculated from the per-
spective of the National Health Care System. RESULTS:
At baseline analysis, life expectancy of pamidronate was
13 quality-adjusted days in CTPs and 30 days in HTPs,
while incremental cost was $1469 in CTPs and $2275 in
HTPs. The incremental cost per QALY gained was $40
in CTPs and $27,857 in HTPs. Sensitivity analysis re-
vealed that the results depended on: 1) the quality of life
correlated with the primary disease, threshold values be-
ing 0.30 (baseline 0.33) in CTPs and 0.42 (baseline 0.73)
in HTPs; 2) the quality of life on pamidronate, threshold
being 0.27 (baseline 0.28) in CTPS and 0.58 in HTPs
(baseline 0.62). and 0.83. CONCLUSIONS: Based upon
the results of this analysis we can conclude that pamidro-
nate is cost-effective in reducing skeletal events of pa-
tients with metastatic breast cancer undergoing chemo-
or hormone-therapy. The variation of the estimates among
the present and the two previous studies can be explained
in terms of model and country differences.
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OBJECTIVE: The objective of this study was to assess
the relationship between haemoglobin levels and quality
of life in cancer patients, looking specifically at breast,
ovarian, lung, and multiple myeloma patients. METH-
ODS: This was a multi-centre cross-sectional study. A to-
tal of 198 patients were recruited from six sites across the
United Kingdom. Patients were asked to complete the
FACT-An, SF-36, and Patient Generated Index (PGI)
upon having their Hb level assessed during a routine
clinic visit. RESULTS: 38% of the patients recruited into
the study had breast cancer, 27% ovarian, 25% lung,
and 10% multiple myeloma. The mean Hb level was
10.9. Analyses were conducted on the data controlling
for age, gender, and time since diagnosis. Significant rela-
tionships were found between all domains of the FACT
with the exception of the social/family domain. Signifi-
